I think SAMBA II has put that technology on our table!
Dr. G. Gwinji, Former Permanent Secretary, Ministry of Health and Child Care of Zimbabwe
SAMBA II delivers innovative assays in an easy-to-use and accessible platform for the diagnosis and treatment monitoring of infectious disease at the point of care. We are committed to expanding our test menu to cover more infectious agents, with hepatitis B and C tests expected to be released in 2020 and other tests including influenza A and B, and other sexually-transmitted infections in development.
In vitro nucleic acid amplification test for the semi-quantitative detection of HIV-1 in human whole blood.
In vitro nucleic acid amplification test for the qualitative detection of HCV viral RNA in human whole blood.
In vitro nucleic acid amplification test for the qualitative detection of SARs-CoV-2 in human nasal and throat swabs.
Nucleic-acid based amplification test for the qualitative detection of nucleic acids from SARS-CoV-2, Influenza A and/or Influenza B in human respiratory specimens (combined nasal and throat, nasal or nasopharyngeal swabs).
Nucleic-acid based amplification test for the qualitative detection of nucleic acids from SARS-CoV-2 and/or Respiratory Syncytial Virus (RSV) in human respiratory specimens (combined nasal and throat/nasal/nasopharyngeal swabs).